Cyteir
99 Hayden Ave
Lexington, MA 02421
Cyteir is a clinical-stage oncology company dedicated to the development of CYT-0851, an oral investigational drug designed to inhibit monocarboxylate transporters. The company's current focus is on advancing CYT-0851 in combination with capecitabine and gemcitabine through a Phase 1/2 clinical study targeting patients with advanced ovarian cancer.
With a pipeline of novel drug candidates aimed at addressing key vulnerabilities in cancer, Cyteir is committed to pioneering therapeutic solutions for patients in need. Their approach emphasizes leveraging cancer's vulnerabilities as a strength in treatment development.
Generated from the website
Also at this address
See a problem?